Analysts have been eager to weigh in on the Healthcare sector with new ratings on Anixa Biosciences (ANIX – Research Report), Roche Holding AG (RHHVF – Research Report) and Bristol-Myers Squibb (BMY – Research Report).
Anixa Biosciences (ANIX)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, with a price target of $12.00. The company’s shares closed last Friday at $3.68.
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Anixa Biosciences is a Moderate Buy with an average price target of $12.00.
See today’s best-performing stocks on TipRanks >>
Roche Holding AG (RHHVF)
Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG today and set a price target of CHF270.00. The company’s shares closed last Thursday at $311.55.
According to TipRanks.com, Field is ranked #5160 out of 8533 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $343.75 average price target, representing a 10.2% upside. In a report issued on July 18, Morgan Stanley also maintained a Hold rating on the stock with a CHF310.00 price target.
Bristol-Myers Squibb (BMY)
In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on Bristol-Myers Squibb. The company’s shares closed last Friday at $60.32.
According to TipRanks.com, Shibutani is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol-Myers Squibb with a $71.40 average price target, a 17.6% upside from current levels. In a report issued on July 18, BMO Capital also maintained a Buy rating on the stock with a $87.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANIX:
